Clinical Trials Logo

Toxemia clinical trials

View clinical trials related to Toxemia.

Filter by:

NCT ID: NCT02867267 Completed - Sepsis Clinical Trials

The Efficacy and Safety of Ta1 for Sepsis

TESTS
Start date: September 6, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether thymalfasin is safe and effective in patients who have sepsis

NCT ID: NCT02837731 Completed - Sepsis Clinical Trials

Fluid Responsiveness Evaluation in Sepsis-associated Hypotension

FRESH
Start date: October 2016
Phase: N/A
Study type: Interventional

This study assesses the mean difference in fluid balance at ICU discharge and associated patient outcomes, based on a dynamic assessment of fluid responsiveness in septic patients with refractory hypotension in an ICU setting.

NCT ID: NCT02820675 Completed - Sepsis Clinical Trials

Quality Improvement in Infection COntrol and Sepsis Management in MOdel Regions

icosmos
Start date: August 2015
Phase: N/A
Study type: Interventional

The German Quality Network Sepsis is an association trying to improve quality of care for patients with sepsis, severe sepsis and septic shock or being in risc thereof. The icosmos trial investigates the impact on the use of routine data, a risk adjustment algorithm and feedback to all hospitals as well as a structured implementation for regular screening for deteriorating patients, and education on in-hospital mortality.

NCT ID: NCT02789995 Completed - Sepsis Clinical Trials

Dysfunctions of Human Muscle Stem Cells in Sepsis

DISCUSS
Start date: June 23, 2016
Phase: N/A
Study type: Interventional

Severe critical illness is often complicated by Intensive Care Unit - Acquired Weakness (ICU-AW), which is associated with increased in and post-ICU mortality, with delayed weaning from mechanical ventilation and with long-term functional. Several mechanisms have been incriminated in the pathophysiology of ICU-AW, but muscle regeneration has not been well investigated in this context, even though its involvement is suggested by the protracted functional consequences of ICU-AW. Recent data suggest that muscle regeneration could be impaired after sepsis, and that Mesenchymal Stem Cells (MSCs) treatment could improve the post-injury muscle recovery.

NCT ID: NCT02748382 Completed - Sepsis Clinical Trials

Fluids in Sepsis and Septic Shock

FISSH
Start date: August 18, 2016
Phase: Phase 2/Phase 3
Study type: Interventional

Despite evidence of the physiologic benefits and possible lower mortality associated with low chloride solutions, normal saline remains the most wildly used fluid in the world. Given uncertainty about the impact of lower chloride versus higher chloride solutions on mortality, it is unlikely that clinical practice will change without new and direct RCT evidence. Editorials published in leading critical care journals have called for RCT's to address this important clinical question. The proposed feasibility RCT will investigate the feasibility of a large-scale trial directly comparing low chloride versus normal chloride for resuscitation in septic shock on patient-important outcomes such as mortality and AKI.

NCT ID: NCT02747121 Completed - Sepsis Clinical Trials

Effects of External Inspection on Sepsis Detection and Treatment

Start date: April 2016
Phase: N/A
Study type: Interventional

External inspections are widely used as means to improve the quality of care. Despite their widespread use, there is limited knowledge about whether and how they affect the quality of care. This study uses inspection with detection and treatment of sepsis in hospitals as a case to evaluate the effect of inspections on the quality of care and to explore how inspections affect the hospitals.

NCT ID: NCT02739152 Completed - Sepsis Clinical Trials

TRIAGE: TRIage of Sepsis At emerGency dEpartment

TRIAGE
Start date: April 2015
Phase:
Study type: Observational

Sepsis is a serious systemic disease defined as a combination of Systemic Inflammation Response Syndrome (SIRS) plus a confirmed or suspected infection. Untreated or inadequately treated cases can lead to severe sepsis or septic shock; being characterized by high mortality and morbidity. Symptoms and signs of sepsis are variable and this makes clinical recognition and assessment very difficult in particular on Emergency Department (ED) patients due to their infectious illness background and the frequent comorbidities. Also, the severity of the condition may not be apparent at initial contact with ED personnel: patients may arrive at ED with mild clinical manifestation and rapidly progress to critical illness, or rather at the opposite others have benign evolution despite a similar symptoms. In these conditions, the main challenge of ED clinicians is differentiating mild infections from life-threatening ones in the heavy workload of ED environment Objective of TRIAGE project is to identify and validate biomarkers able to predict the clinical worsening of patients freshly admitted at Emergency Department. Targeted population is adult patients freshly admitted at ED, whom blood samples will serve to validate candidate markers.

NCT ID: NCT02738164 Completed - Sepsis Clinical Trials

SEPSIS 3 Critera for Risk Stratification in Emergency Patients

SCREEN
Start date: May 2016
Phase: N/A
Study type: Observational

Investigators aim to evaluate the SEPSIS 3 criterion for "sepsis" and "septic shock" in a prospective manner. Investigators will evaluate qSOFA performances and other SEPSIS 3 criterion in a population of emergency patients with infection

NCT ID: NCT02734550 Completed - Septic Shock Clinical Trials

(1,3)-β-D-glucan Based Diagnosis of Invasive Candida Infection in Sepsis

CandiSep
Start date: September 12, 2016
Phase: N/A
Study type: Interventional

This prospective randomized multicenter study evaluates whether the decision to prescribe antifungals guided by (1,3)-β-D-glucan in comparison to standard of care shortens time to antifungal therapy and reduces mortality in patients with severe sepsis or septic shock and a high risk of invasive candida infection.

NCT ID: NCT02730624 Completed - Clinical trials for Early Phase of Severe Sepsis and Septic Shock

Piperacillin/Tazobactam in Critically Ill Patients With Severe Sepsis and Septic Shock

Start date: March 2014
Phase: Phase 4
Study type: Interventional

This is prospective study to assess the pharmacodynamics (t>MIC) of 4.5 g every 6 h of piperacillin/tazobactam in patients with early phase of severe sepsis/septic shock following administration by a 30 min infusion. Clinical and laboratory data such as age, sex, body weight, electrolyte, vital signs, APACHAE II score, BUN, Cr and fluid balance will be collected. Fifty patients will be enrolled in this study. Piperacillin pharmacokinetic study will be carried out during the piperacillin/tazobactam therapy. Each patient received 4.5 g every 6 h of piperacillin/tazobactam within 24 h of severe sepsis or septic shock, blood samples (approximately 3 ml) will be obtained by direct venipuncture at the following time: 0, 0-0.5, 0.5-2, 2-4 and 4-6 h after piperacillin/tazobactam therapy. Concentration of piperacillin in plasma will be simulated in Monte Carlo technique to get PK/PD index and reported to % PTA and % CFR.